- Home
- Latest
- By speciality
- Biology
- Bone
- Brain and nervous system
- Breast
- Colorectal and gastrointestinal
- Community
- Diagnostics
- Drug development
- Epidemiology and prevention
- Haematology oncology
- Head and neck
- Hepatobiliary pancreatic
- Lung and pleura
- Melanoma and skin
- Ovary and gynaecology
- Paediatric
- Prostate and urology
- Psycho social
- Radiotherapy
- Sarcomas
- Surgery
- Other
- By congress
- By continent
- Latest technologies
- Most viewed
- Archive
- Contact us
- FAQ's
- Register
ESMO 33, Europe, Hepatobiliary pancreatic
Flash player required
You do not have the correct version of the flash player required to view this content. Click here to install the free Adobe flash player.
Prof. Matthias Löhr
Karolinska Institute, Sweden
New drug substantially extends survival in pancreatic cancer.
Specialities
- Biology (58)
- Bone (16)
- Brain and nervous system (14)
- Breast (143)
- Colorectal and gastrointestinal (32)
- Community (61)
- Diagnostics (27)
- Drug development (49)
- Epidemiology and prevention (42)
- Haematology oncology (39)
- Head and neck (17)
- Hepatobiliary pancreatic (15)
- Lung and pleura (30)
- Melanoma and skin (22)
- Ovary and gynaecology (29)
- Paediatric (17)
- Prostate and urology (32)
- Psycho social (19)
- Radiotherapy (18)
- Sarcomas (13)
- Surgery (24)
Content is the view and comment of the speakers or author and not of sponsoring companies or organisations. Organisation logo does not indicate endorsement.
Comments on this video Report unsuitable comment
No comments have been made on this video yet, be the first to voice your opinion, use the form on the right.
Add a comment